Gary Bridger - 06 Jun 2022 Form 4 Insider Report for X4 Pharmaceuticals, Inc (XFOR)

Reporting relationship: Director
Issuer ticker: XFOR
Reported as of: 06 Jun 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Jun 2022, 16:17:34 UTC
Prior SEC filing: 02 Jun 2021
Next SEC filing: 14 Jun 2023
Source filing: View source filing
Reporting owner signature: Derek M. Meisner, attorney-in-fact

Key filing fact

Gary Bridger filed Form 4 for X4 Pharmaceuticals, Inc (XFOR) on 27 Jun 2022.

Key facts

This page summarizes Gary Bridger's Form 4 filing for X4 Pharmaceuticals, Inc (XFOR).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 27 Jun 2022, 16:17.

Change

Previous filing in this sequence was filed on 02 Jun 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

XFOR transaction

Common Stock

Award

Transaction value: $0
Shares: +6,667
Change %
Price: $0.000000
Shares after: 6,667
Date: 06 Jun 2022
Ownership: Direct
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Represents an annual grant of restricted stock units ("RSUs") for service as a director to the Issuer. The RSUs will vest in two equal annual installments on June 6, 2023 and June 6, 2024, subject to the Reporting Person continuing to provide service to the Issuer through the applicable vesting date.

Footnote F2

Represents unvested RSUs.